Posted on

cbd benefits for glaucoma

Cbd benefits for glaucoma

En español | Cannabidiol, or CBD, a chemical component of marijuana and hemp that doesn’t get users high, is increasingly touted by proponents as an alternative treatment for numerous ailments. But an organization of eye doctors is advising people not to try CBD as a remedy for glaucoma, a disease for which older Americans are at higher risk.

A recent study suggests that the marijuana product might worsen the condition

The study, coupled with other research using human subjects, “raises a legitimate concern about whether CBD may raise eye pressure and so serve as a potential risk factor for glaucoma,” said lead researcher Alex Straiker, an associate scientist in the university’s Department of Psychological and Brain Sciences.

by Patrick J. Kiger, AARP, January 24, 2019

Purpose: The purpose of this study was to assess the effect on intraocular pressure (IOP) and the safety and tolerability of oromucosal administration of a low dose of delta-9-tetrahydrocannabinol (Delta-9-THC) and cannabidiol (CBD).

Results: Two hours after sublingual administration of 5 mg Delta-9-THC, the IOP was significantly lower than after placebo (23.5 mm Hg vs. 27.3 mm Hg, P=0.026). The IOP returned to baseline level after the 4-hour IOP measurement. CBD administration did not reduce the IOP at any time. However, the higher dose of CBD (40 mg) produced a transient elevation of IOP at 4 hours after administration, from 23.2 to 25.9 mm Hg (P=0.028). Vital signs and visual acuity were not significantly changed. One patient experienced a transient and mild paniclike reaction after Delta-9-THC administration.

Patients and methods: A randomized, double-masked, placebo-controlled, 4 way crossover study was conducted at a single center, using cannabis-based medicinal extract of Delta-9-THC and CBD. Six patients with ocular hypertension or early primary open angle glaucoma received a single sublingual dose at 8 AM of 5 mg Delta-9-THC, 20 mg CBD, 40 mg CBD, or placebo. Main outcome measure was IOP. Secondary outcomes included visual acuity, vital signs, and psychotropic effects.